Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: Proof of sequence specificity in cell culture and in vivo rat experiments

Antisense and Nucleic Acid Drug Development

Volumn 7, Issue 6, 1997, Pages 567-573

  Stec, Wojciech J ^a   Cierniewski, CzesŁaw S ^b   Okruszek, Andrzej ^a   Kobylańska, Anna ^a   PawŁowska, Zofia ^b   KozioŁkiewicz, Maria ^a   Pluskota, Elzbieta ^b   Maciaszek, Anna ^a   Rȩbowska, Beata ^a   Stasiak, Marta ^b  

^a CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIASTEREOISOMER; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; START CODON;

ANIMALIA;

EID: 0031457916     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1997.7.567     Document Type: Article

References (11)

1. AUWERX, J., BOUILLON, R., COLLEN, D., and GEBOERS, J. (1988). Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8, 68-72.
2. BEAUCAGE, S.L., and IYER, R.P. (1992). Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48, 2223-2311.
3. BENIMETSKAYA, L., BERTON, M., KOLBANOVSKY, A., BENIMETSKY, S., and STEIN, C.A. (1997). Formation of G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kB p65) "antisense" oligonucleotide. Nucleic Acids Res. 25, 2648-2656.
4. BISHOP, J.S., GUY-CAFFEY, J.K., OJWANG, J.O., SMITH, S.R., HOGAN, M.E., COSSUM, P.A., RANDO, R.F., and CHAUDHARY, N. (1996). Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol. Chem. 271, 5698-5703.
5. BOSMA, P.J., VAN DEN BERG, E.A., KOOISTRA, T., SIEMIENIAK, D.R., and SLIGHTOM, J.L. (1988). Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J. Biol. Chem. 263, 9129-9141.
6. CIERNIEWSKI, Cz.S., BABIŃSKA, A., ŚWIA̧TKOWSKA, M., WILCZYṄSKA, M., OKRUSZEK, A., and STEC, W.J. (1995a). Inhibition by modified oligodeoxynucleotides of the expression of type 1 plasminogen activator inhibitor in human endothelial cells. Eur. J. Biochem. 227, 494-499.
7. CIERNIEWSKI, Cz.S., PLUSKOTA, E., KRZESŁOWSKA, J., FIJAŁKOWSKA, I., KOBYLAŃSKA, A., KOZIOŁKIEWICZ, M., OKRUSZEK, A., and STEC, W.J. (1995b). Inhibition by modified oligodeoxynucleotides of the expression of type 1 plasminogen activator inhibitor in human endothelial cells. Thromb. Haemost. 73, 1007.
8. ERICKSON, L.A., FICI, G.J., LUND, J.E., BOYLE, T.P., POLITES, H.G., and MAROTTI, K.R. (1990). Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature 346, 74-76.
9. FISHER, T.L., TERHORST, T., CAO, X., and WAGNER, R.W. (1993). Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21, 3857-3865.
10. HAMSTEN, A., DE FAIRE, U., WALLDIUS, G., DAHLEN, G., SZAMOSI, A., LANDOU, C., BLOMBACK, M., and WIMAN, B. (1987). Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction. Lancet 2, 3-9.
11. WIMAN, B., and HAMSTEN, A. (1990). The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb. Hemost. 26, 207-216.